Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

November 30, 2002

Primary Completion Date

March 31, 2004

Study Completion Date

November 30, 2010

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

IDEC-114

Dose Group 1 - 125 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 2 - 250 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 3 - 375 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions Dose Group 4 - 500 mg/m2 x 4 infusions \& 375 mg/m2 Rituxan x 4 infusions

Trial Locations (22)

1906

Research site, Philadelphia

2115

Research site, Boston

10021

Research site, New York

14263

Research site, Buffalo

14642

Research site, Rochester

20007

Research site, Washington D.C.

22908

Research site, Charlottesville

27710

Research site, Durham

29210

Research site, Columbia

33612

Research site, Tampa Bay

35294

Research site, Birmingham

48202

Research site, Detroit

55905

Research site, Rochester

60153

Research site, Maywood

60611

Research site, Chicago

68198

Research site, Omaha

77030

Research site, Houston

80010

Research site, Aurora

85724

Research site, Tucson

90095

Research site, Los Angeles

92121

Research site, San Diego

92658

Research site, Newport Beach

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY

NCT00048555 - Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter